NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 1998
Industry: Formulation and production of encapsulated vitamins, nutrients, and nutritional supplements.
Operations: The Company operates as a single segment, providing contract manufacturing and proprietary products (via subsidiaries Millennium Health Products and CellLife International). It focuses on large, global clients and recently expanded capacity with a tablet manufacturing facility and a new build-to-suit headquarters in Carlsbad, California, scheduled for occupancy in early 1999.

Key Financial Metrics (Fiscal Year 1998)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 37.3% ($18.5 million) driven by new customers and a significant expansion in international sales, which rose from $1.9 million in 1997 to $14.9 million in 1998.
• Profitability Surge: Income from operations increased 430% to $9.6 million. This was primarily due to an $8.3 million increase in gross profit, attributed to negotiated raw material savings and improved manufacturing efficiencies.
• Margin Expansion: Gross profit margins improved to 27.6% from 21.1% in 1997. The 1997 margin had been depressed by product mix shifts and raw material write-offs.
• Expense Management: Selling, general, and administrative (SG&A) expenses increased in absolute dollars to $9.1 million but decreased as a percentage of sales to 13.4% (from 17.4%). Increases in employee benefits (due to a full year of the defined benefit pension plan) and professional fees were offset by a decline in bad debt expense and the expiration of a royalty agreement.
• Backlog: Order backlog increased to $24.0 million as of September 17, 1998, from $18.1 million the prior year.

Outlook, Risks, and Contingencies

• Capital Expenditures: The Company anticipates capital expenditures of approximately $12.0 million in fiscal 1999, primarily for the new headquarters and a leased warehouse/blending facility. Funding is expected from cash holdings, operating cash flow, and potential debt/equity financing.
• Year 2000 Compliance: The Company is replacing financial and manufacturing software systems to address Year 2000 issues, with implementation expected by March 31, 1999. Estimated costs are $1 million, of which $100,000 will be expensed. Risks include potential system failures or vendor non-compliance.
• Customer Concentration: Two customers, Nu Skin International and NSA International, represented 54% of total sales in 1998. Loss of either would have a material adverse impact.
• Regulatory Environment: Operations are subject to FDA, FTC, and other regulations regarding labeling, advertising, and safety. The Company adheres to USP specifications and FDA Good Manufacturing Practices.
• Liquidity: The Company maintains a $3.0 million revolving line of credit (unused as of June 30, 1998) secured by receivables and inventory. Management believes current resources and financing options are sufficient for anticipated needs.

Investor Verification Checklist

• Customer Dependency: Verify the stability of relationships with Nu Skin International and NSA International, which account for over half of revenue.
• Capital Expenditure Funding: Confirm the ability to fund the projected $12 million in 1999 capital expenditures without diluting shareholders or over-leveraging the balance sheet.
• Year 2000 Readiness: Assess the progress of software replacement and vendor compliance to mitigate operational disruption risks.
• Related Party Transactions: Review the $282,815 in noninterest-bearing loans to the Chairman and President, and the $100,000 annual commission paid to the CEO's in-laws.
• Pension Liability: Monitor the funded status of the defined benefit pension plan, which had an accrued liability of $662,564 as of June 30, 1998.